神威藥業(02877.HK)公佈年度業績 毛利率升至74.9% 經營活動產生現金淨額大增73.5%
格隆匯3月30日丨神威藥業(02877.HK)公佈，截至2020年12月31日止年度，公司營業額為人民幣26.56億元，淨利潤（減值撥備前）達5億元，集團於該減值撥備前錄得的淨利潤率為18.8%，比去年18.6%大致相同；每股盈利為人民幣39分，建議派發末期股息每股人民幣21分。
集團於年內毛利率為74.9%，比去年73.2%略有上升，主要是由於較高毛利率的產品利潤貢獻比例持續增加。
期間公司現金流量仍然保持強勁。於2020年，經營活動產生的現金淨額從人民幣3.68億元增長73.5%至人民幣6.39億元。
儘管在疫情下2020年上半年個別產品啟動上線進度受到影響，集團互聯網數字營銷2020年實現了線上銷售人民幣8,350萬元，比去年增長182.0%。於2020年，集團天貓藥品旗艦店正式上線，同時亦與國內主流醫藥電商平台包括京東、天貓、平安好醫生、壹藥網、藥師幫等B2B和B2C等加強戰略合作，打造數字化營銷生態圈，快速拉動銷售規模。
公司表示，集團多年來整合了眾多優秀的產品羣，目前集團已經擁有超過400個產品文號，30餘個自主知識產權的獨家產品，涵蓋心腦血管、抗病毒、骨傷科、兒科、婦科、神經科、消化科、眼科、腫瘤及免疫用藥等不同治療領域的17大品類產品羣，600多箇中藥配方顆粒品種。集團成為醫藥行業中藥品品類最全的現代中藥企業之一。
集團目前亦正全力打造集團數字化營銷生態圈，為營銷各業務板塊賦能，以互聯網+助力集團大健康產業營銷數字化轉型，強化B2B、B2C、O2O、自營網上旗艦店建設，抓好醫藥營銷模式創新和現代化管理，目標是到2023年實現線上銷售成為集團營銷的主力軍之一。
在中長期發展戰略上，集團將持續強化戰略產品的研發，堅持以創新藥開發為主，圍繞心腦血管疾病、兒科病、腫瘤、骨科病、婦科病、老年病等中醫藥優勢領域，創制具有國內領先水平、被現代醫學體系認可、具有臨牀優勢和特色的創新藥、古代經典名方、大健康食品等，並加快創新組分中藥塞絡通膠囊三期臨牀及其他新品上市的節奏。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
